Literature DB >> 16946301

WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.

Toshinao Kawai1, Uimook Choi, Lanise Cardwell, Suk See DeRavin, Nora Naumann, Narda L Whiting-Theobald, Gilda F Linton, Jaehyun Moon, Philip M Murphy, Harry L Malech.   

Abstract

WHIM(warts, hypogammaglobulinemia, recurrent bacterial infection, and myelokathexis) syndrome is a rare immunodeficiency caused in many cases by autosomal dominant C-terminal truncation mutations in the chemokine receptor CXCR4. A prominent and unexplained feature of WHIM is myelokathexis (hypercellularity with apoptosis of mature myeloid cells in bone marrow and neutropenia). We transduced healthy human CD34(+) peripheral blood-mobilized stem cells (PBSCs) with retrovirus vector encoding wild-type (wt) CXCR4 or WHIM-type mutated CXCR4 and studied these cells ex vivo in culture and after engraftment in a nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse xenograft model. Neither wt CXCR4 nor mutated CXCR4 transgene expression itself enhanced apoptosis of neutrophils arising in transduced PBSC cultures even with stimulation by a CXCR4 agonist, stromal cell-derived factor-1 (SDF-1 [CXCL12]). Excess wt CXCR4 expression by transduced human PBSCs enhanced marrow engraftment, but did not affect bone marrow (BM) apoptosis or the release of transduced leukocytes into PB. However, mutated CXCR4 transgene expression further enhanced BM engraftment, but was associated with a significant increase in apoptosis of transduced cells in BM and reduced release of transduced leukocytes into PB. We conclude that increased apoptosis of mature myeloid cells in WHIM is secondary to a failure of marrow release and progression to normal myeloid cell senescence, and not a direct effect of activation of mutated CXCR4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946301      PMCID: PMC1785067          DOI: 10.1182/blood-2006-05-025296

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

Review 1.  Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.

Authors:  Neal Flomenberg; John DiPersio; Gary Calandra
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

2.  Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors.

Authors:  C Tian; J Bagley; D Forman; J Iacomini
Journal:  Gene Ther       Date:  2006-04       Impact factor: 5.250

3.  Myelokathexis: a rare form of chronic benign granulocytopenia.

Authors:  R Bassan; P Viero; B Minetti; B Comotti; T Barbui
Journal:  Br J Haematol       Date:  1984-09       Impact factor: 6.998

4.  'Myelokathexis'. Neutropenia with marrow hyperplasia.

Authors:  S O'Regan; A J Newman; R C Graham
Journal:  Am J Dis Child       Date:  1977-06

Review 5.  Progress toward effective gene therapy for chronic granulomatous disease.

Authors:  Harry L Malech; Uimook Choi; Sebastian Brenner
Journal:  Jpn J Infect Dis       Date:  2004-10       Impact factor: 1.362

6.  The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Authors:  Neal Flomenberg; Steven M Devine; John F Dipersio; Jane L Liesveld; John M McCarty; Scott D Rowley; David H Vesole; Karin Badel; Gary Calandra
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

7.  Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells.

Authors:  Joby L McKenzie; Olga I Gan; Monica Doedens; John E Dick
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

8.  G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells.

Authors:  Hyun Kyung Kim; Maria De La Luz Sierra; Cassin Kimmel Williams; A Virginia Gulino; Giovanna Tosato
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

9.  A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells.

Authors:  T Tanaka; M Tsudo; H Karasuyama; F Kitamura; T Kono; M Hatakeyama; T Taniguchi; M Miyasaka
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

10.  Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice.

Authors:  T Tanaka; F Kitamura; Y Nagasaka; K Kuida; H Suwa; M Miyasaka
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  39 in total

Review 1.  Regulation of neutrophil trafficking from the bone marrow.

Authors:  Ryan B Day; Daniel C Link
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

Review 2.  Neutrophils cascading their way to inflammation.

Authors:  Christian D Sadik; Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2011-08-11       Impact factor: 16.687

3.  WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

Authors:  Qian Liu; Haoqian Chen; Teresa Ojode; Xiangxi Gao; Sandra Anaya-O'Brien; Nicholas A Turner; Jean Ulrick; Rosamma DeCastro; Corin Kelly; Adela R Cardones; Stuart H Gold; Eugene I Hwang; Daniel S Wechsler; Harry L Malech; Philip M Murphy; David H McDermott
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

4.  Chromothriptic cure of WHIM syndrome.

Authors:  David H McDermott; Ji-Liang Gao; Qian Liu; Marie Siwicki; Craig Martens; Paejonette Jacobs; Daniel Velez; Erin Yim; Christine R Bryke; Nancy Hsu; Zunyan Dai; Martha M Marquesen; Elina Stregevsky; Nana Kwatemaa; Narda Theobald; Debra A Long Priel; Stefania Pittaluga; Mark A Raffeld; Katherine R Calvo; Irina Maric; Ronan Desmond; Kevin L Holmes; Douglas B Kuhns; Karl Balabanian; Françoise Bachelerie; Stephen F Porcella; Harry L Malech; Philip M Murphy
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

Review 5.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

Review 6.  Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind.

Authors:  Bertrand Boisson; Pierre Quartier; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2015-01-31       Impact factor: 7.486

7.  A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

Authors:  David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

Review 8.  Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil?

Authors:  Alejandro A Schäffer; Christoph Klein
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-12

Review 9.  Genetic insights into congenital neutropenia.

Authors:  Christoph Klein; Karl Welte
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

Review 10.  WHIM syndrome: congenital immune deficiency disease.

Authors:  Toshinao Kawai; Harry L Malech
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.